February 13, 2018 / 1:44 PM / 6 months ago

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

Feb 13 (Reuters) - Advaxis Inc:

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

* ADVAXIS INC - COMPANY WILL CONTINUE ASSESSING PARTNERSHIP OPPORTUNITIES FOR POTENTIAL COMMERCIALIZATION OF AXALIMOGENE FILOLISBAC IN EUROPE

* ADVAXIS- DECIDED TO ALIGN, SIMPLIFY STRATEGY BY USING AXALIMOGENE FILOLISBAC EXCLUSIVELY IN ALL ONGOING AND PLANNED HPV-RELATED CANCER CLINICAL TRIALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below